use of factor viia or a factor viia equivalent, parts kit and method to prevent or mitigate one or more late trauma complications, and methods to reduce the number of days a trauma patient is hospitalized after trauma to reduce the number of days a trauma patient spends in an intensive care unit after trauma, to improve lung function in a trauma patient, to reduce the risk of developing acute lung injury and / or acute respiratory distress syndrome in a patient. to reduce the risk of developing disseminated intravascular coagulation in a trauma patient, to reduce the risk of developing systemic inflammatory response syndrome in a trauma patient, to reduce the risk of developing multiple organ failure in a trauma patient , to reduce the risk of death in a trauma patient and to prevent or mitigate one or more late trauma complications.

摘要

USE OF VIIA FACTOR OR VIIA FACTOR EQUIVALENT, PARTS KIT AND METHOD TO PREVENT OR ATTENTION OF ONE OR MORE LATE COMPLICATIONS OF TRAUMA, AND METHODS TO REDUCE THE NUMBER OF DAYS IN WHICH A TRAUMA PATIENT IS HOSPITALIZED, REDUCE THE NUMBER OF DAYS THAT A TRAUMA PATIENT ENDS IN AN INTENSIVE TREATMENT UNIT AFTER TRAUMA, TO IMPROVE LUNG FUNCTION IN A TRAUTE PATIENT, TO REDUCE THE RISK OF DEVELOPING PULMONARY INJURY AND SUFFERING PATIO TO REDUCE THE RISK OF DEVELOPING DISSEMINATED INTRAVASCULAR COAGULATION IN A TRAUMA PATIENT, TO REDUCE THE RISK OF SYSTEMIC INFLAMMATORY RESPONSE IN A TRAUMA DEVOLU DERUHUS , TO REDUCE THE RISK OF DEATH IN A trauma patient and to prevent or mitigate one or more late trauma complications. refers to the use of Factor VIIa or equivalent of Factor VIIa to manufacture a drug to prevent late complications in trauma patients.